# BioCryst to Report Second Quarter 2026 Financial Results on August 5
Canonical URL: https://biopharmsignal.com/news/BCRX/biocryst-to-report-second-quarter-2026-financial-results-on-august-5-9520c4fa
Ticker: BCRX
Company: BioCryst Pharmaceuticals
Source: BioCryst Pharmaceuticals
Published: 2026-07-22 11:00 EST
Original Source URL: https://ir.biocryst.com/news-releases/news-release-details/biocryst-report-second-quarter-2026-financial-results-august-5
## Summary

The Investor Relations website contains information about BioCryst Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

## Article Body
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com .

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn .

BCRXW

Contact:

Investors: investorrelations@biocryst.com

Media: media@biocryst.com
## Recent Company News
- 2026-07-22 11:00 EST — [BioCryst to Report Second Quarter 2026 Financial Results on August 5](https://biopharmsignal.com/news/BCRX/biocryst-to-report-second-quarter-2026-financial-results-on-august-5-9520c4fa) — Source: BioCryst Pharmaceuticals
- 2026-07-15 11:00 EST — [BioCryst Appoints David W. Jenkins as Chief Scientific Officer](https://biopharmsignal.com/news/BCRX/biocryst-appoints-david-w-jenkins-as-chief-scientific-officer-a24b8329) — Source: BioCryst Pharmaceuticals
- 2026-07-02 11:00 EST — [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-afb4cc8d) — Source: BioCryst Pharmaceuticals
- 2026-06-29 11:00 EST — [BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility](https://biopharmsignal.com/news/BCRX/biocryst-sharpens-scientific-focus-on-external-innovation-with-wind-down-of-inte-83b84c41) — Source: BioCryst Pharmaceuticals
- 2026-06-12 11:00 EST — [BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/BCRX/biocryst-presents-new-clinical-data-and-real-world-evidence-demonstrating-impact-0fbfa230) — Source: BioCryst Pharmaceuticals
## Related News
- 2026-07-22 21:05 EST — SUPN — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d)
- 2026-07-22 20:15 EST — MOH — [Molina Healthcare Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32)
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)